uniQure N.V annual ebitda
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
uniQure N.V EBITDA Growth & History (QURE)
uniQure N.V's calculated EBITDA was −$170.6M for fiscal 2025.
View full uniQure N.V company overviewuniQure N.V annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$170.6M | $1.1M | — |
| 2024 | 2024-12-31 | −$171.7M | $99.3M | — |
| 2023 | 2023-12-31 | −$271.0M | −$136.3M | — |
| 2022 | 2022-12-31 | −$134.6M | −$452.5M | — |
| 2021 | 2021-12-31 | $317.9M | $432.7M | — |
| 2020 | 2020-12-31 | −$114.8M | −$307,000 | — |
| 2019 | 2019-12-31 | −$114.5M | −$38.7M | — |
| 2018 | 2018-12-31 | −$75.8M | −$12.0M | — |
| 2017 | 2017-12-31 | −$63.8M | $2.6M | — |
| 2016 | 2016-12-31 | −$66.4M | $305,000 | — |
| 2015 | 2015-12-31 | −$66.8M | −$15.1M | — |
| 2014 | 2014-12-31 | −$51.7M | — | — |
uniQure N.V quarterly ebitda
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$59.9M | −$19.7M | — |
| Q1 2026 | 2026-03-31 | −$42.8M | −$8.0M | — |
| Q4 2025 | 2025-12-31 | −$48.1M | −$6.7M | — |
| Q3 2025 | 2025-09-30 | −$47.4M | −$10.2M | — |
| Q2 2025 | 2025-06-30 | −$40.2M | $1.1M | — |
| Q1 2025 | 2025-03-31 | −$34.8M | $16.8M | — |
| Q4 2024 | 2024-12-31 | −$41.5M | $16.1M | — |
| Q3 2024 | 2024-09-30 | −$37.2M | $42.0M | — |
| Q2 2024 | 2024-06-30 | −$41.3M | $21.1M | — |
| Q1 2024 | 2024-03-31 | −$51.6M | $20.0M | — |
| Q4 2023 | 2023-12-31 | −$57.6M | −$86.4M | — |
| Q3 2023 | 2023-09-30 | −$79.3M | −$21.9M | — |
| Q2 2023 | 2023-06-30 | −$62.5M | −$8.4M | — |
| Q1 2023 | 2023-03-31 | −$71.6M | −$19.7M | — |
| Q4 2022 | 2022-12-31 | $28.8M | $24.9M | +635.48% |
| Q3 2022 | 2022-09-30 | −$57.4M | −$14.2M | — |
| Q2 2022 | 2022-06-30 | −$54.1M | −$453.9M | — |
| Q1 2022 | 2022-03-31 | −$52.0M | −$9.4M | — |
| Q4 2021 | 2021-12-31 | $3.9M | $9.9M | — |
| Q3 2021 | 2021-09-30 | −$43.2M | −$3.6M | — |
| Q2 2021 | 2021-06-30 | $399.8M | $436.2M | — |
| Q1 2021 | 2021-03-31 | −$42.6M | −$9.9M | — |
| Q4 2020 | 2020-12-31 | −$6.0M | $25.3M | — |
| Q3 2020 | 2020-09-30 | −$39.6M | −$10.0M | — |
| Q2 2020 | 2020-06-30 | −$36.4M | −$8.8M | — |
| Q1 2020 | 2020-03-31 | −$32.7M | −$6.8M | — |
| Q4 2019 | 2019-12-31 | −$31.2M | −$9.0M | — |
| Q3 2019 | 2019-09-30 | −$29.6M | −$13.6M | — |
| Q2 2019 | 2019-06-30 | −$27.7M | −$8.1M | — |
| Q1 2019 | 2019-03-31 | −$25.9M | −$7.9M | — |
| Q4 2018 | 2018-12-31 | −$22.2M | −$1.1M | — |
| Q3 2018 | 2018-09-30 | −$16.0M | −$8.5M | — |
| Q2 2018 | 2018-06-30 | −$19.5M | −$2.3M | — |
| Q1 2018 | 2018-03-31 | −$18.0M | −$128,000 | — |
| Q4 2017 | 2017-12-31 | −$21.2M | −$5.8M | — |
| Q3 2017 | 2017-09-30 | −$7.5M | $5.2M | — |
| Q2 2017 | 2017-06-30 | −$17.2M | $3.4M | — |
| Q1 2017 | 2017-03-31 | −$17.9M | −$137,000 | — |
| Q4 2016 | 2016-12-31 | −$15.4M | — | — |
| Q3 2016 | 2016-09-30 | −$12.7M | — | — |
| Q2 2016 | 2016-06-30 | −$20.6M | — | — |
| Q1 2016 | 2016-03-31 | −$17.8M | — | — |
uniQure N.V ebitda trends
Over the last five fiscal years, uniQure N.V's ebitda decreased from −$114.8M to −$170.6M, a change of −$55.8M. The latest reported quarter, Q2 2026, shows −$59.9M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review uniQure N.V source filings ↗Community posts
uniQure reports longer Huntington’s follow-up, with mixed statistical results
uniQure ($QURE) released additional Phase I/II results for AMT-130 in Huntington’s disease. Among 15 high-dose patients followed for 36 months, the company reported 80% slower decline on the composite disease-rating scale against an externa ...
